{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+and+Other+Malignant+Neoplasms+of+Skin&page=3", "query": { "condition": "Melanoma and Other Malignant Neoplasms of Skin", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 83, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+and+Other+Malignant+Neoplasms+of+Skin&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+and+Other+Malignant+Neoplasms+of+Skin&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T02:37:10.664Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02452424", "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Gastrointestinal Stromal Tumor (GIST)", "Ovarian Cancer" ], "interventions": [ { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-07-02", "completion_date": "2018-10-12", "has_results": true, "last_update_posted_date": "2020-03-05", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452424" }, { "nct_id": "NCT07492680", "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab FDC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-07-27", "completion_date": "2032-05-20", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 16, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492680" }, { "nct_id": "NCT00101270", "title": "Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Colon Cancer", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Melanoma", "Recurrent Nasopharyngeal Cancer", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 24, "start_date": "2005-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101270" }, { "nct_id": "NCT03728842", "title": "Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma; Renal Cell Carcinoma" ], "interventions": [ { "name": "Blood collection for laboratory studies", "type": "OTHER" }, { "name": "Data collection from medical record", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2004-01-04", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03728842" }, { "nct_id": "NCT02711345", "title": "A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Non-Small-Cell Lung Carcinoma", "Melanoma", "Other Solid Tumors" ], "interventions": [ { "name": "LTT462", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 65, "start_date": "2016-04-15", "completion_date": "2018-11-21", "has_results": true, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711345" }, { "nct_id": "NCT06326411", "title": "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oncology", "MEK Mutation", "RAF Gene Mutation", "Ras (KRAS or NRAS) Gene Mutation", "Melanoma", "NSCLC", "Glioma", "Solid Tumor, Adult", "MAPK Pathway Gene Mutation" ], "interventions": [ { "name": "NST-628", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nested Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2024-04-09", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 17, "location_summary": "San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Westwood, Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06326411" }, { "nct_id": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Triple Negative Breast Cancer", "HR+/HER2- Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" }, { "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2016-12-19", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983045" }, { "nct_id": "NCT01239134", "title": "Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies" ], "interventions": [ { "name": "TRX518", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2010-10", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239134" }, { "nct_id": "NCT01586195", "title": "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 31, "start_date": "2011-10-31", "completion_date": "2015-04-30", "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 15, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586195" }, { "nct_id": "NCT00002854", "title": "High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 33, "start_date": "1994-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-08-26", "last_synced_at": "2026-10-13T02:37:10.664Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002854" } ] }